PD07-03 MICHIGAN PROSTATE SCORE (MIPS): AN ANALYSIS OF A NOVEL URINARY BIOMARKER PANEL FOR THE PREDICTION OF PROSTATE CANCER AND ITS IMPACT ON BIOPSY RATES (2017)

You have accessJournal of UrologyProstate Cancer: Detection & Screening II1 Apr 2017PD07-03 MICHIGAN PROSTATE SCORE (MIPS): AN ANALYSIS OF A NOVEL URINARY BIOMARKER PANEL FOR THE PREDICTION OF PROSTATE CANCER AND ITS IMPACT ON BIOPSY RATES Amir H. Lebastchi, Christopher M. Russell, Alexander M. Helfand, Takahiro Osawa, Javed Siddiqui, Rabia Siddiqui, Arul M. Chinnaiyan, Priya Kunju, Rohit Mehra, Debbie Snyder, Scott A. Tomlins, Jont T. Wei, and Todd M. Morgan Amir H. LebastchiAmir H. Lebastchi More articles by this author , Christopher M. RussellChristopher M. Russell More articles by this author , Alexander M. HelfandAlexander M. Helfand More articles by this author , Takahiro OsawaTakahiro Osawa More articles by this author , Javed SiddiquiJaved Siddiqui More articles by this author , Rabia SiddiquiRabia Siddiqui More articles by this author , Arul M. ChinnaiyanArul M. Chinnaiyan More articles by this author , Priya KunjuPriya Kunju More articles by this author , Rohit MehraRohit Mehra More articles by this author , Debbie SnyderDebbie Snyder More articles by this author , Scott A. TomlinsScott A. Tomlins More articles by this author , Jont T. WeiJont T. Wei More articles by this author , and Todd M. MorganTodd M. Morgan More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.378AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The Michigan Prostate Score (MiPS) is a validated and commercially available early detection test for prostate cancer combining serum PSA with urinary PCA3 and T2:ERG expression. This novel biomarker reports individual patient risk estimates for biopsy detection of any MiPS and of high-grade (Gleason score >6) prostate cancer HG MiPS. We investigated the impact of MiPS on clinical decision-making and prostate biopsy frequency rates and correlated MiPS and HG MiPS with final biopsy pathology results. METHODS MiPS testing was offered to men referred for initial or repeat prostate biopsy at a single, tertiary institution as an alternative to proceeding directly to a biopsy between October 2013 and January 2015. Patient characteristics, PSA, PCA3, T2:ERG, and biopsy pathology were analyzed to see how MiPS and HG MiPS risk prediction models affected the decision for prostate biopsy as well as biopsy pathology. One-way ANOVA was used to correlate MiPS scores with biopsy rates and clinical outcomes. RESULTS 149 men underwent MiPS testing, of whom 67.8% had not undergone a prior prostate biopsy. Median age was 65.2, and median PSA was 9.5 ng/ml. The mean predicted risks for detection of any and high-grade cancer were 41.5% and 26.0%, respectively. The 73 men (49%) who proceeded to prostate needle biopsy had higher MiPS (52.7% vs. 30.7%, p<0.001) and HG MiPS scores (35.2% vs. 18.2%, p<0.001) than those who did not undergo biopsy. Among those biopsied, MiPS, HG MiPS, PCA3, and T2:ERG were significantly higher in those with cancer (all p<0.05) found on biopsy. PSA alone was not associated with cancer diagnosis (p=0.82). CONCLUSIONS The combination of urinary PCA3 and T2:ERG in a test panel for prostate cancer reduced the use of prostate biopsy by 51% among men referred for prostate biopsy. MiPS and MiPS HG were closely correlated with the presence of any cancer and high-grade cancer, respectively. These findings support the clinical utility and validity of MiPS for stratifying prostate cancer risk and guiding high-yield biopsy utilization. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e128 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Amir H. Lebastchi More articles by this author Christopher M. Russell More articles by this author Alexander M. Helfand More articles by this author Takahiro Osawa More articles by this author Javed Siddiqui More articles by this author Rabia Siddiqui More articles by this author Arul M. Chinnaiyan More articles by this author Priya Kunju More articles by this author Rohit Mehra More articles by this author Debbie Snyder More articles by this author Scott A. Tomlins More articles by this author Jont T. Wei More articles by this author Todd M. Morgan More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...